Drug Profile
ZD 4953
Latest Information Update: 09 Dec 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Analgesics
- Mechanism of Action Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 09 Dec 1999 Discontinued-II for Pain in United Kingdom (PO)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 12 Dec 1997 Phase-II clinical trials for Pain in United Kingdom (PO)